Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accounts Payables: 2010-2024

Historic Accounts Payables for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Dec 2024 value amounting to $39.1 million.

  • Vanda Pharmaceuticals' Accounts Payables rose 21.16% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.6 million, marking a year-over-year increase of 21.16%. This contributed to the annual value of $39.1 million for FY2024, which is 1.63% up from last year.
  • Vanda Pharmaceuticals' Accounts Payables amounted to $39.1 million in FY2024, which was up 1.63% from $38.5 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Accounts Payables high stood at $45.6 million for FY2022, and its period low was $31.5 million during FY2020.
  • In the last 3 years, Vanda Pharmaceuticals' Accounts Payables had a median value of $39.1 million in 2024 and averaged $41.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first skyrocketed by 32.27% in 2022, then dropped by 15.57% in 2023.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Accounts Payables stood at $31.5 million in 2020, then increased by 9.30% to $34.4 million in 2021, then spiked by 32.27% to $45.6 million in 2022, then fell by 15.57% to $38.5 million in 2023, then climbed by 1.63% to $39.1 million in 2024.